Scarica l'app Stockscreener
161.06
0.54%
-0.88
Dopo l'orario di chiusura:
160.71
-0.35
-0.22%
Precedente Chiudi:
$161.94
Aprire:
$163.5
Volume 24 ore:
111.22K
Relative Volume:
0.54
Capitalizzazione di mercato:
$6.49B
Reddito:
-
Utile/perdita netta:
$-77.61M
Rapporto P/E:
-70.09
EPS:
-2.2979
Flusso di cassa netto:
-
1 W Prestazione:
-1.07%
1M Prestazione:
-0.01%
6M Prestazione:
-10.99%
1 anno Prestazione:
+147.02%
Intervallo 1D:
$160.44
$164.81
Intervallo di 1 settimana:
$159.98
$170.86
Portata 52W:
$62.18
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Nome
Belite Bio Inc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare BLTE vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
161.06 | 6.52B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-26 | Iniziato | BofA Securities | Buy |
| 2026-01-06 | Iniziato | Morgan Stanley | Overweight |
| 2025-12-02 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-11-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-11-20 | Iniziato | Mizuho | Neutral |
| 2023-12-14 | Iniziato | Maxim Group | Buy |
| 2023-07-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Iniziato | SVB Securities | Outperform |
| 2022-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-01 | Iniziato | The Benchmark Company | Buy |
Mostra tutto
Belite Bio Inc Adr Borsa (BLTE) Ultime notizie
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - The Manila Times
Belite Bio (NASDAQ:BLTE) Stock Rating Lowered by Zacks Research - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Belite Bio CFO Hao-Yuan Chuang Sells 367 ADS Under Rule 10b5-1 Plan - Kalkine Media
Belite Bio CEO Lin Yu-Hsin Reports Sale of 365 ADS Under Rule 10b5-1 Plan - Kalkine Media
Benchmark reiterates Belite Bio stock rating on FDA priority review - Investing.com
Benchmark reiterates Belite Bio stock rating on FDA priority review By Investing.com - Investing.com Canada
Mizuho raises Belite Bio stock price target to $220 on NDA progress - Investing.com
Belite Bio CFO Chuang Hao-Yuan sells $66,187 in shares By Investing.com - Investing.com South Africa
Belite Bio CEO Lin Yu-Hsin sells company stock, over $65,000 - Investing.com Canada
Hao-Yuan Chuang Sells 367 Shares of Belite Bio (NASDAQ:BLTE) Stock - MarketBeat
Yu-Hsin Lin Sells 365 Shares of Belite Bio (NASDAQ:BLTE) Stock - MarketBeat
Belite Bio CFO Chuang Hao-Yuan sells $66,187 in shares - Investing.com
Belite Bio (BLTE) Could Be 21% Below Fair Value As FDA Priority Review Lands - Sahm
Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ... By GuruFocus - Investing.com Canada
Belite Bio Q2 2026 Earnings Call Transcript - MarketBeat
Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips - Investing.com Canada
Belite Bio Q2 Earnings Call Highlights - Yahoo Finance
Belite Bio (NASDAQ:BLTE) Stock Price Down 7.2%Should You Sell? - MarketBeat
Belite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS - MarketBeat
Belite Bio Gains FDA Priority Review for Tinlarebant as Losses Widen on Commercial Build-Out - TipRanks
Belite Bio (NASDAQ: BLTE) wins FDA Priority Review and reports wider Q2 2026 loss - Stock Titan
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update - The Manila Times
BLTE (NASDAQ: BLTE) files Form 144 for 93,800 ADS sale - Stock Titan
Yi Chen Raises Approval Odds and Lifts Tinlarebant-Focused 12‑Month Price Target to $214 While Reiterating Buy Rating - TipRanks
Belite Bio stock price target raised to $214 by H.C. Wainwright on FDA review - Investing.com Nigeria
Cantor Fitzgerald reiterates Belite Bio stock rating on regulatory outlook By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Belite Bio stock rating on regulatory outlook - Investing.com
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA - TradingView
HC Wainwright Issues Positive Forecast for Belite Bio (NASDAQ:BLTE) Stock Price - MarketBeat
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 - The Manila Times
FDA grants priority review for Belite Bio’s Stargardt treatment By Investing.com - Investing.com Australia
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease - TipRanks
FDA grants priority review for Belite Bio’s Stargardt treatment - Investing.com
Belite Bio (NASDAQ: BLTE) wins FDA priority review for tinlarebant in Stargardt disease - Stock Titan
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
How Belite Bio Inc (BLTE) Affects Rotational Strategy Timing - Stock Traders Daily
The Manufacturers Life Insurance Company Purchases New Shares in Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results - markets.businessinsider.com
Renaissance Technologies LLC Makes New Investment in Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat
Belite Bio (BLTE) Expected to Post Quarterly Earnings on Monday - MarketBeat
Perceptive Advisors LLC Has $24.23 Million Stock Position in Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat
ADAR1 Capital Management LLC Sells 12,959 Shares of Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat
(BLTE) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Price to sales forward of Belite Bio, Inc. ADR – FWB:D01 - TradingView
Belite Bio, Inc. ADR Revenue Breakdown – FWB:D01 - TradingView
Belite Bio, Inc. Sponsored ADR $BLTE Shares Acquired by Affinity Asset Advisors LLC - MarketBeat
Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases - MarketBeat
Belite Bio stock price target maintained at $200 by H.C. Wainwright - Investing.com UK
Belite Bio Inc Adr Azioni (BLTE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):